Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)
2015년 6월 10일 업데이트: AbbVie (prior sponsor, Abbott)
Safety and Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis in Routine Clinical Practice
The research question explored in this study was whether the effectiveness and safety of adalimumab in participants with ankylosing spondylitis was maintained during long-term therapy in routine clinical practice in Germany.
연구 개요
상태
완전한
정황
상세 설명
This was a postmarketing observational study (PMOS) for participants with insufficiently controlled, moderate to severe, active AS who were eligible for adalimumab therapy.
Participants started treatment with adalimumab under normal clinical settings in Germany.
Enrolled participants were followed during adalimumab therapy .
Participants were assessed during regular clinic visits for up to 24 months and 359 clinicians (rheumatologists/orthopedists/general practitioners/internist) participated in the study.
Since this was an observational trial, not all doctors followed the stated age limitations and some participants under the age of 18 were enrolled.
연구 유형
관찰
등록 (실제)
4681
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
샘플링 방법
비확률 샘플
연구 인구
Participants with AS in routine clinical practice.
설명
Inclusion Criteria:
- Participants with active, AS for at least 4 weeks (BASDAI greater than or equal to 4).
- Participants who failed treatment with two non-steroidal anti-inflammatory drugs (NSAIDs).
- No contraindications for anti-tumor necrosis factors (TNF) therapy.
Exclusion Criteria:
1. Participants who do not meet the above listed inclusion criteria.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: 케이스 전용
- 시간 관점: 유망한
코호트 및 개입
그룹/코호트 |
|---|
|
Ankylosing spondylitis
Participants with ankylosing spondylitis
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The BASDAI was a six question, participant-reported measure of overall disease activity that probed the level of fatigue, neck/back/hip pain, peripheral joint swelling and pain, localized tenderness, as well as morning stiffness severity and duration.
It was scored on a numerical rating scale that ranged from 0 (no symptoms) to 10 (severe symptoms), and the minimum clinically important difference (MCID) was 1.0.
The final BASDAI score was calculated using the following equation, in which 01 - 06 represents the question number: (BASDAI01 + BASDAI02 + BASDAI03 + BASDAI04 + BASDAI05/2 + BASDAI06*1.25/2)/5.
The scale for question 6 was reduced to 0-8 since BASDAI06 was multiplied by 1.25.
Data are reported as the mean change total score from baseline (Month 0).
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The BASFI was a ten question, participant-reported measure that evaluated physical function.
Each question was scored on a numerical rating scale that ranged from 0 (no functional impairment) to 10 (maximal impairment), and the MCID was 0.7.
The mean of the ten questions was the total BASFI score.
Data are reported as the mean change of total score from baseline (Month 0).
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Number of Participants With Drug-Related Adverse Events (AEs)
기간: From signing of informed consent up to 24 months
|
An adverse event/adverse experience was any reaction, side effect or other untoward event associated with the use of a drug in humans, whether or not the event was considered drug related.
This included adverse events occurring from accidental or deliberate drug overdose, from drug abuse, or from drug withdrawal.
Exacerbations of pre-existing conditions are also considered adverse events.
Data presented are adverse events that are drug-related and are detailed in the adverse event section of this report.
|
From signing of informed consent up to 24 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mean Number of Involved Peripheral Joints
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Peripheral joints were assessed by Tender Joint Counts (TJC) and Swollen Joint Counts (SJC), using pressure and joint manipulation during physical examination.
Seventy-eight TJC and 76 SJC were evaluated and a score of 0 (not tender or swollen) or 1 (tender or swollen) was assigned for each joint with a higher total score indicating a greater number of involved joints.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants With Extraspinal Manifestations
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Extraspinal manifestations (enthesitis, dactylitis, uveitis, psoriasis, and Inflammatory Bowel Disease (IBD)) were assessed by investigators and reported on the basis of their clinical evaluation and participant records.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Erythrocyte Sedimentation Rate (ESR)
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Plasma concentrations of ESR were assessed as a marker of systemic inflammation that provided insights into the overall anti-inflammatory effect of rheumatologic therapies.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Plasma Concentrations of C-Reactive Protein (CRP)
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Plasma concentrations of CRP were assessed as a marker of systemic inflammation that provided insights into the overall anti-inflammatory effect of rheumatologic therapies.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Bath Ankylosing Spondylitis-Global (BAS-G) Score
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The BAS-G was a participant-reported instrument with two items.
In the first item, the participant rated the effect of their disease over the last week, and in the second item, the participant rated the effect of their disease over the previous 6 months.
Each item of the BAS-G was scored on a scale ranging from 0 (no effect) to 10 (very severe effect).
The mean of the two scores was the total BAS-G score and the MCID was 1.5.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Global Assessment of Disease Activity Score
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Global Assessment of Disease Activity was a participant-reported measure that evaluated disease activity.
It was scored on a scale that ranged from 0 to 10; lower scores indicated better patient status.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Participant Fatigue Score
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Using the BASDAI questionnaire, participants assessed the overall level of fatigue/tiredness experienced by him/her.
It was scored on a numerical rating scale from 0 (no symptoms) to 10 (severe symptoms).
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Participant Pain Score
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Using the BASDAI questionnaire, participants assessed the overall level of AS neck, back or hip pain experienced by him/her.
It was scored on a numerical rating scale from 0 (no symptoms) to 10 (severe symptoms).
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants With Morning Stiffness
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Morning stiffness was a participant-reported assessment.
The number of participants with morning stiffness were assessed at each visit.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Duration of Morning Stiffness
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Participants accessed the duration of morning stiffness in 15 minute intervals from 0 to 2 hours.
Data are reported as the mean duration of morning stiffness ± standard deviation.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS) Improvement Criteria
기간: At 3, 6, 9, 12, 18, and 24 months
|
This is a four domain (participant global assessment of disease activity, assessment of spinal pain, assessment of function (BASFI), and assessment of duration/severity of morning stiffness (mean of BASDAI questions 5 and 6)), participant-reported assessment scored on a scale from 0 (best) to 10 (worst).
To qualify for a 20% improvement, participants were required to have an improvement of greater than or equal to 20% and greater than or equal to 1 unit in at least 3 domains, and no worsening of greater than or equal to 20% and greater than or equal to 1 unit in the remaining domain.
To achieve a 40% improvement, participants were required to have an improvement of greater than or equal to 40% and greater than or equal to 2 units in at least 3 domains, and no worsening at all in the remaining domain.
|
At 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants Achieving ASAS Partial Remission Criteria
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
This is a four domain (participant global assessment of disease activity, assessment of spinal pain, assessment of function (BASFI), and assessment of duration/severity of morning stiffness (mean of BASDAI questions 5 and 6)), participant-reported assessment scored on a scale from 0 (best) to 10 (worst).
To qualify for a partial remission, participants had to have values of 2 or less (on a scale of 10) in each of the 4 domains.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants With Impairment in Daily Activities During the Last 4 Weeks
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The impairment of daily activities was based on participant recall of events that occurred over the 4 weeks before the visit.
Percentage of participants with impairment for 0, less than 7, 7 to 14, and greater than 14 days was assessed.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants Who Missed Work Days Due to Ankylosing Spondylitis (AS) in the Previous 12 Months
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Mean Missed Work Days Due to Ankylosing Spondylitis in the Previous 12 Months
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Percentage of Participants With In-Patient Hospitalization Due to Ankylosing Spondylitis in the Previous 12 Months
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Mean Days of In-Patient Hospitalization Due to Ankylosing Spondylitis in the Previous 12 Months
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Percentage of Participants on Adalimumab Monotherapy
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Percentage of Participants With Concomitant Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Percentage of Participants With Concomitant Pain Relief/Anti-Inflammatory Agents
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Participants with concomitant pain relief/anti-inflammatory agents like analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, and systemic glucocorticoids were assessed during the study period.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Equivalent Dose of Prednisolone
기간: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The mean equivalent dose of prednisolone was calculated based on the International Standard for comparison of different glucocorticoid products.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
- 연구 책임자: Bianca Wittig, MD, AbbVie Deutschland GmbH & Co. KG, Medical Department
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
유용한 링크
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2006년 1월 1일
기본 완료 (실제)
2014년 5월 1일
연구 완료 (실제)
2014년 5월 1일
연구 등록 날짜
최초 제출
2010년 3월 1일
QC 기준을 충족하는 최초 제출
2010년 3월 2일
처음 게시됨 (추정)
2010년 3월 3일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2015년 7월 9일
QC 기준을 충족하는 마지막 업데이트 제출
2015년 6월 10일
마지막으로 확인됨
2015년 6월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .